Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLASE, INCBIOL · Entity 11470 | Director | June 11, 2021 | June 14, 2021 |
| Guardant Health, Inc.GH · Entity 3238 | Chief Medical Officer | November 01, 2019 | November 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLASE, INC
Report date June 11, 2021 · Filed June 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2031-06-11 | Direct | 104,603 |
Reported balance
After 2021-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-11 · Grant · Acquired 104,603 · Balance 104,603 F1: Of the stock appreciation rights subject to this SAR, one-fourth of the stock appreciation rights vest on each of the third, sixth, ninth, and twelfth-month anniversaries of the date of grant. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 138,000 |
Reported balance
After 2021-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-11 · Grant · Acquired 138,000 · Balance 138,000 F2: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F3: The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the stock appreciation rights subject to this SAR, one-fourth of the stock appreciation rights vest on each of the third, sixth, ninth, and twelfth-month anniversaries of the date of grant.
F2: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.
F3: The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023.
Guardant Health, Inc.
Report date November 01, 2019 · Filed November 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 82,015 |
Ending reported balance
After 2019-11-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-11-01 · Exercise / conversion · Acquired 2,305 · Balance 84,320 Row 2 · 2019-11-01 · Exercise / conversion · Acquired 3,459 · Balance 87,779 Row 3 · 2019-11-01 · Sale · Disposed 5,764 · Balance 82,015 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F2: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $69.62 to $70.34. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2027-05-30 | Direct | 13,066 |
Reported balance
After 2019-11-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-01 · Exercise / conversion · Disposed 2,305 · Balance 13,066 F3: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2028-08-21 | Direct | 39,196 |
Reported balance
After 2019-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-01 · Exercise / conversion · Disposed 3,459 · Balance 39,196 F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share.
F2: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $69.62 to $70.34. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
F3: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017.
F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2021 Filed Jun 14, 2021 21:04 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 138,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040464 · doc4.xml · derivative · entry 2 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 138,000 shares Expires not disclosed F2 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F3 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023. F3 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:04 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantStock Appreciation Right · Derivative | 104,603 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-040464 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,603 Underlying: Common Stock · 104,603 shares Expires 2031-06-11 F1 · derivative.exercise_date: Of the stock appreciation rights subject to this SAR, one-fourth of the stock appreciation rights vest on each of the third, sixth, ninth, and twelfth-month anniversaries of the date of grant. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 09:45 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-045864 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,856 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. Read SEC document |
| May 13, 2020 Filed May 28, 2020 12:03 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantStock Option (right to buy) · Derivative | 176,045 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-032537 · doc4.xml · derivative · entry 2 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,084 Underlying: Common Stock · 176,045 shares Expires 2030-05-13 F3 · derivative.exercise_date: The stock option vests and is immediately exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service. Read SEC document |
| May 13, 2020 Filed May 28, 2020 12:03 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 155,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032537 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,856 Underlying: Common Stock · 155,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award, subject to the Reporting Person's continued service. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 3,459 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-19-013353 · wf-form4_157299112194362.xml · derivative · entry 5 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,196 Underlying: COMMON STOCK · 3,459 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 2,305 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-013353 · wf-form4_157299112194362.xml · derivative · entry 4 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,066 Underlying: COMMON STOCK · 2,305 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,764 | $69.96 | $403,249.44 |
DisclosureSEC source: 0001628280-19-013353 · wf-form4_157299112194362.xml · nonDerivative · entry 3 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,015 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $69.62 to $70.34. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 3,459 | $8.80 | $30,439.20 |
DisclosureSEC source: 0001628280-19-013353 · wf-form4_157299112194362.xml · nonDerivative · entry 2 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,305 | $4.18 | $9,634.90 |
DisclosureSEC source: 0001628280-19-013353 · wf-form4_157299112194362.xml · nonDerivative · entry 1 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 3,458 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · derivative · entry 9 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,655 Underlying: COMMON STOCK · 3,458 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018. F9 · derivative.expiration_date: The expiration date of August 22, 2028 reported in the Reporting Person's prior Form 4 filings was in error. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 2,307 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · derivative · entry 8 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,371 Underlying: COMMON STOCK · 2,307 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017. F7 · derivative.expiration_date: The expiration date of May 31, 2027 reported in the Reporting Person's prior Form 4 filings was in error. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 500 | $107.18 | $53,590.00 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 7 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,015 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,596 | $106.47 | $1,021,686.12 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 6 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,515 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F5 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $106.11 to $107.02. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 25,520 | $105.69 | $2,697,208.80 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 5 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,111 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F4 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $105.11 to $106.10. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,060 | $104.80 | $1,683,088.00 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 4 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,631 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F3 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $104.11 to $105.10. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,399 | $103.79 | $1,183,102.21 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 3 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,691 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $103.10 to $104.08. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 3,458 | $8.80 | $30,430.40 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 2 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 16:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,307 | $4.18 | $9,643.26 |
DisclosureSEC source: 0001628280-19-010686 · wf-form4_156572842087153.xml · nonDerivative · entry 1 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 10:59 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 70,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045268 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,640 Underlying: Common Stock · 70,606 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the nine month anniversary of the date of the award. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the nine month anniversary of the date of the award. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 29,069 | $0.00 Strike: $94.47 | $0.00 |
DisclosureSEC source: 0001628280-19-009999 · wf-form4_156503981135972.xml · derivative · entry 2 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,069 Underlying: COMMON STOCK · 29,069 shares Expires 2029-07-31 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:17 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantCOMMON STOCK | 9,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-009999 · wf-form4_156503981135972.xml · nonDerivative · entry 1 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,325 Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:30 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,690 | $80.00 | $135,200.00 |
DisclosureSEC source: 0001628280-19-007062 · wf-form4_155839143419311.xml · nonDerivative · entry 1 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,729 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 01, 2019 Filed May 3, 2019 18:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 2,306 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-19-005841 · wf-form4_155692094161070.xml · derivative · entry 6 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,113 Underlying: COMMON STOCK · 2,306 shares Expires 2028-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018 F8 · derivative.expiration_date: The expiration date of August 21, 2028 reported in the Reporting Person's Form 3 filed on October 3, 2019 and Form 4 filed on April 17, 2019 was in error. Read SEC document |
| May 01, 2019 Filed May 3, 2019 18:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,536 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-005841 · wf-form4_155692094161070.xml · derivative · entry 5 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,678 Underlying: COMMON STOCK · 1,536 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017. F6 · derivative.expiration_date: The expiration date of April 30, 2027 reported in the Reporting Person's Form 3 filed on October 3, 2019 and Form 4 filed on April 17, 2019 was in error. Read SEC document |
| May 01, 2019 Filed May 3, 2019 18:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,200 | $65.62 | $78,744.00 |
DisclosureSEC source: 0001628280-19-005841 · wf-form4_155692094161070.xml · nonDerivative · entry 4 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,419 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.02 to $65.98, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2019 Filed May 3, 2019 18:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,642 | $64.49 | $170,382.58 |
DisclosureSEC source: 0001628280-19-005841 · wf-form4_155692094161070.xml · nonDerivative · entry 3 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,619 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $4.18 or $8.80 per share. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.95 to $64.75, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2019 Filed May 3, 2019 18:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,306 | $8.80 | $20,292.80 |
DisclosureSEC source: 0001628280-19-005841 · wf-form4_155692094161070.xml · nonDerivative · entry 2 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 18:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,536 | $4.18 | $6,420.48 |
DisclosureSEC source: 0001628280-19-005841 · wf-form4_155692094161070.xml · nonDerivative · entry 1 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Issuer's 2018 Employee Stock Purchase Plan that were not included in the Reporting Person's last Form 4 filing. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 6,916 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 15 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,419 Underlying: COMMON STOCK · 6,916 shares Expires 2028-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018 Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 17,676 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 14 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,214 Underlying: COMMON STOCK · 17,676 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F10 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 21,652 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 13 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,679 Underlying: COMMON STOCK · 21,652 shares Expires 2024-10-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The exercise price of $1.42 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option on September 2, 2015, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 18,848 | $72.98 | $1,375,527.04 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 10 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,631 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share. F6 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $72.92 to $73.86. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 27,396 | $71.66 | $1,963,197.36 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 9 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,479 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share. F5 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $71.50 to $71.76. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 6,916 | $8.80 | $60,860.80 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 8 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 17,676 | $4.18 | $73,885.68 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 7 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 21,652 | $1.43 | $30,962.36 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 6 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 45,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 12 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,331 Underlying: COMMON STOCK · 45,000 shares Expires 2024-10-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The exercise price of $1.42 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option on September 2, 2015, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 45,000 | $76.56 | $3,445,200.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 5 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,631 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share. F4 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $76.44 to $76.64. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 45,000 | $1.43 | $64,350.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 4 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 45,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 11 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,331 Underlying: COMMON STOCK · 45,000 shares Expires 2024-10-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The exercise price of $1.42 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option on September 2, 2015, thereafter vests in equal monthly installments over 36 months. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,500 | $76.05 | $1,026,675.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 3 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,631 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share. F3 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $75.92 to $76.29. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 31,500 | $73.98 | $2,330,370.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 2 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,131 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share. F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $73.86 to $74.19. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 45,000 | $1.43 | $64,350.00 |
DisclosureSEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 1 Lanman Richard B. · CIK 0001721003 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2018 Filed May 14, 2018 17:46 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 81,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029954 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,034 Underlying: Common Stock · 81,034 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award. F2 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award. Read SEC document |
| November 08, 2017 Filed Nov 9, 2017 19:25 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantStock Option (right to buy) · Derivative | 9,868 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001209191-17-060094 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,201 Underlying: Common Stock · 9,868 shares Expires 2027-11-08 F1 · derivative.exercise_date: The stock option vests and is exercisable in equal monthly installments over a consecutive 6-month period, commencing December 10, 2017. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 12:00 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantStock Option (right to buy) · Derivative | 135,333 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001209191-17-058738 · doc4.xml · derivative · entry 1 Lanman Richard B. · CIK 0001721003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,333 Underlying: Common Stock · 135,333 shares Expires 2027-11-01 F1 · derivative.exercise_date: The stock option vests as follows: 7,053 option shares vest on November 10, 2017 with the remainder vesting in equal monthly installments over a consecutive 6-month period, commencing December 10, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.